Indonesia vs Somalia: Average cost of multi drug-resistant tuberculosis treatment
Indonesia
1,138 constant 2022 US$
in 2024
Somalia
1,178 constant 2022 US$
in 2021
Indonesia rank
41st
Somalia rank
40th
Average cost of multi drug-resistant tuberculosis treatment over time
- Indonesia
- Somalia
How they compare
Somalia currently reports 1,178 constant 2022 US$ against 1,138 constant 2022 US$ in Indonesia, a difference of 40 constant 2022 US$.
The two have swapped places 2 times across 5 shared years of data; in 2017 it was Indonesia ahead.
Indonesia ranks 41st and Somalia ranks 40th of 92 countries.
Across the 2 decades both report, Indonesia averaged higher in 1 and Somalia in 1.
Head to head by decade
| Decade | Indonesia | Somalia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,463 constant 2022 US$ | 1,490 constant 2022 US$ | 26.33 constant 2022 US$ | Somalia |
| 2020s | 1,808 constant 2022 US$ | 1,340 constant 2022 US$ | 467.5 constant 2022 US$ | Indonesia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Indonesia or Somalia?
- Somalia, at 1,178 constant 2022 US$ against 1,138 constant 2022 US$ in Indonesia as of 2021.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Indonesia and Somalia?
- 40 constant 2022 US$, with Somalia ahead.
- How many years of comparable data are there for Indonesia and Somalia?
- 5 years are reported by both, from 2017 to 2021.
- How do Indonesia and Somalia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Indonesia ranks 41st and Somalia ranks 40th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.